Research in animals suggests that the new compound is neither toxic nor hallucinogenic and that it may help treat a range of psychiatric disorders, including depression and addiction, and possibly anxiety and post-traumatic stress disorder (PTSD).
Ibogaine is a psychedelic drug extracted from the roots of iboga, a shrub native to the rainforests of West Africa.
While there have been no placebo-controlled clinical trials of ibogaine, anecdotal reports and small open-label studies suggest that it can reduce drug cravings and prevent relapse.
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers